DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that the U.S. Patent and Trademark Office has issued a new patent extending QuantRx’ lateral flow testing intellectual property suite. This new patent offers significant new protection as QuantRx enters the market with its hypersensitive point-of-care lateral flow based system. Coupling this technology with the patented Q-reader technology enables QuantRx to provide CLIA (Clinical Laboratory Improvement Amendments) waived Point-of-Care (POC) tests that other technologies cannot offer.
